http://depts.washington.edu/herpes/publications.htm#vaccines

Immunotherapy of recurrent genital herpes with recombinant herpes
simplex virus type 2 glycoproteins D and B: results of a
placebo-controlled vaccine trial

Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AGM, Hohman P,
Lekstrom J, Cox E, Nakamura M, Sekulovich R, Izu A, Dekker C, Corey L.

Abstract:

To determine the safety, immunogenicity, and efficacy of a recombinant
herpes simplex virus type 2 glycoprotein D and B vaccine in the
treatment of recurrent genital herpes, a randomized, placebo-controlled
trial was held at two referral centers. Healthy patients with 4-14
recurrences per year received injections of both glycoproteins in MF59
adjuvant or of MF59 alone at 0, 2, 12, and 14 months. For 18 study
months, the rate and number of recurrences, the duration and severity of
the first confirmed recurrence, vaccine immunogenicity, and rates of
local and systemic reactions were determined. The monthly rate of
recurrence was not significantly improved, but the duration and severity
of the first study outbreak was reduced significantly by vaccination.
Glycoprotein-specific and neutralizing antibodies were boosted by
vaccination for the duration of the study. This vaccine is safe and
immunogenic and ameliorated an observed first postvaccination genital
recurrence, but it does not reduce recurrence frequency.